Back to News
Market Impact: 0.1
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Source: Business Wire
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Lantern Pharma announced that its Open-Medicine AI unit will present on the agentic AI drug-development market, user needs, product-development roadmap, platform economics, and benchmarking. The provided article text contains no financial results, forecasts, product metrics, or transaction details, limiting the immediate market significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LTRN0.45
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Chinese authorities reportedly in possession of F-35 components in Hong Kong
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- How Meta took the lead in the race for the post-smartphone world
- Markets are rapidly coming around to the reality that the Fed has a lot more work to do
- SoftBank shares jump over 7% after $11.1 billion bond issuance to fund OpenAI bet
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts